Key Points
- Director Gary Fischetti purchased 1,000 Anika Therapeutics shares at $20.75 each, investing $20,750 and increasing his direct ownership by 1.92% to 53,015 shares.
- Anika reported quarterly EPS of $0.42, well above the $0.03 consensus estimate, while revenue of $32.61 million also exceeded expectations of $29.21 million. Analysts expect a full-year loss of $0.74 per share.
- ANIK recently traded at $19.19, near its 52-week high of $21.11. Analyst views are mixed, producing a consensus “Hold” rating and an average price target of $21.00.
Anika Therapeutics Inc. (NASDAQ:ANIK - Get Free Report) Director Gary Fischetti bought 1,000 shares of the stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $20.75 per share, for a total transaction of $20,750.00. Following the completion of the purchase, the director directly owned 53,015 shares in the company, valued at approximately $1,100,061.25. This trade represents a 1.92% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Anika Therapeutics Stock Performance
ANIK opened at $19.19 on Thursday. Anika Therapeutics Inc. has a fifty-two week low of $7.92 and a fifty-two week high of $21.11. The firm has a 50-day moving average of $15.45 and a 200 day moving average of $14.00. The firm has a market cap of $256.76 million, a P/E ratio of -71.07 and a beta of 0.20.
Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.03 by $0.39. Anika Therapeutics had a negative net margin of 3.14% and a positive return on equity of 0.20%. The business had revenue of $32.61 million for the quarter, compared to analyst estimates of $29.21 million. Equities research analysts predict that Anika Therapeutics Inc. will post -0.74 earnings per share for the current fiscal year.
Institutional Trading of Anika Therapeutics
Hedge funds have recently made changes to their positions in the stock. CWM LLC grew its holdings in shares of Anika Therapeutics by 14.5% in the fourth quarter. CWM LLC now owns 8,537 shares of the biotechnology company's stock worth $82,000 after purchasing an additional 1,080 shares during the last quarter. Corient Private Wealth LLC raised its holdings in Anika Therapeutics by 4.3% during the 4th quarter. Corient Private Wealth LLC now owns 32,224 shares of the biotechnology company's stock valued at $310,000 after buying an additional 1,324 shares during the last quarter. Diker Management LLC boosted its position in Anika Therapeutics by 2.4% during the 4th quarter. Diker Management LLC now owns 58,210 shares of the biotechnology company's stock valued at $559,000 after buying an additional 1,371 shares during the period. Man Group plc grew its holdings in Anika Therapeutics by 11.4% in the 3rd quarter. Man Group plc now owns 14,778 shares of the biotechnology company's stock worth $139,000 after acquiring an additional 1,510 shares during the last quarter. Finally, Cerity Partners LLC increased its position in shares of Anika Therapeutics by 5.2% in the fourth quarter. Cerity Partners LLC now owns 31,775 shares of the biotechnology company's stock valued at $305,000 after acquiring an additional 1,575 shares during the period. 91.53% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
ANIK has been the subject of several recent research reports. Barrington Research set a $21.00 target price on shares of Anika Therapeutics in a research note on Thursday, July 30th. B. Riley Financial boosted their price objective on shares of Anika Therapeutics from $18.00 to $21.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of Anika Therapeutics in a report on Wednesday, June 24th. Finally, Wall Street Zen raised shares of Anika Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 1st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $21.00.
Check Out Our Latest Stock Report on ANIK
About Anika Therapeutics
(
Get Free Report)
Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika's proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.
The company's core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
